Statistics

Total Visits

Views
Long-Term (104 Week) Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Pooled Safety Analysis of Three Phase III, Randomized, Controlled Trials48

Select a period of time:

Number of views in the range

Views
Long-Term (104 Week) Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Pooled Safety Analysis of Three Phase III, Randomized, Controlled Trials29

Views

Views
January 20250
February 20251
March 202515
April 202513
May 20250
June 20250
July 20250
Download CSV file
 untranslated
 untranslated

Top country views

Views
Singapore15
Hong Kong10
United Kingdom2
Spain1
United States1
 

Top cities views

Views
Hong Kong10
Council Bluffs1